Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 1:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 1,652 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Schizophrenia Spectrum and Other Psychotic Disorders Clear all
Completed Early Phase 1 Interventional Accepts healthy volunteers

Cannabinoids, Neural Synchrony, and Information Processing

NCT00708994
View directory record Official record
Conditions
Cannabis, Psychotic Disorders
Interventions
THC, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Oct 21, 2026, 1:41 AM EDT
Completed Phase 2 Interventional Results available

A Study of ALKS 3831 in Adults With Schizophrenia

NCT01903837
View directory record Official record
Conditions
Schizophrenia
Interventions
Samidorphan (Low Dose), Samidorphan (Medium Dose), Samidorphan (High Dose), Placebo, Olanzapine
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
50
States / cities
Little Rock, Arkansas • Anaheim, California • Costa Mesa, California + 43 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Oct 21, 2026, 1:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Peer-delivered and Technology-Assisted Integrated Illness Management and Recovery

NCT04481737
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Major Depressive Disorder, Recurrent, Obesity, Cardiovascular Diseases, Diabetes, Smoking, Blood Pressure Disorders, Cholesterol, Elevated
Interventions
Peer-delivered and Technology Support Integrated Illness Management and Recovery, Peer support
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Oct 21, 2026, 1:41 AM EDT
Recruiting Phase 2Phase 3 Interventional

MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction

NCT06191965
View directory record Official record
Conditions
Schizophrenia and Related Disorders, Mitochondrial Alteration, Cognitive Impairment
Interventions
MitoQ, Placebo
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 35 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
New Haven, Connecticut • Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 21, 2026, 1:41 AM EDT
Terminated Not applicable Interventional Results available

Individualized Repetitive Transcranial Magnetic Stimulation for Auditory Verbal Hallucinations

NCT05319080
View directory record Official record
Conditions
Schizophrenia and Related Disorders
Interventions
Repetitive Transcranial Magnetic Stimulation (rTMS)
Device
Lead sponsor
Columbia University
Other
Eligibility
22 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Oct 21, 2026, 1:41 AM EDT
Completed Not applicable Interventional Results available

Brain Stimulation and Cognitive Training

NCT03338673
View directory record Official record
Conditions
Bipolar Disorder, Schizo Affective Disorder, Schizophrenia
Interventions
tDCS, BrainHQ
Device · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Oct 21, 2026, 1:41 AM EDT
Terminated Not applicable Interventional Results available

Transcranial Magnetic Stimulation for the Treatment of Auditory Hallucinations in Schizophrenia

NCT01595503
View directory record Official record
Conditions
Schizophrenia
Interventions
rTMS with fMRI-based targeting, rTMS with landmark-based targeting
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 60 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 8, 2021 · Synced Oct 21, 2026, 1:41 AM EDT
Completed Phase 4 Interventional

Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia

NCT00080327
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Wallingford, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 11, 2013 · Synced Oct 21, 2026, 1:41 AM EDT
Completed Phase 2 Interventional Results available

Safety and Effectiveness of D-serine in Schizophrenia

NCT00322023
View directory record Official record
Conditions
Schizophrenia
Interventions
D-serine
Drug
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 60 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
New Haven, Connecticut • Glen Oaks, New York • Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Oct 21, 2026, 1:41 AM EDT
Completed No phase listed Observational

Central Nervous System Disease in HIV-infected Children on HAART

NCT00110331
View directory record Official record
Conditions
HIV Infections, Central Nervous System Diseases
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Oct 21, 2026, 1:41 AM EDT
Completed Phase 4 Interventional

Risperidone Augmentation in Patients With Schizophrenia

NCT00289861
View directory record Official record
Conditions
Schizophrenia
Interventions
Risperidone, placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 31, 2013 · Synced Oct 21, 2026, 1:41 AM EDT
Not listed Phase 1 Interventional

Families Coping With Mental Illness Program

NCT00435721
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Psychoeducation
Behavioral
Lead sponsor
North Suffolk Mental Health Association
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
2
States / cities
Belmont, Massachusetts • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 15, 2007 · Synced Oct 21, 2026, 1:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Get Moving and Get Well - Pilot Study

NCT01884025
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depression, Post Traumatic Stress Disorder
Interventions
Get Moving and Get Well, Health and Humor Class
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
North Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Nov 5, 2018 · Synced Oct 21, 2026, 1:41 AM EDT
Completed Not applicable Interventional

Contingency Management for Problematic Behavior Reduction in the Community

NCT06486584
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Anosognosia
Interventions
Contingency Management
Behavioral
Lead sponsor
Laureate Institute for Brain Research, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Oct 21, 2026, 1:41 AM EDT
Completed Not applicable Interventional

Cognitive Remediation for Schizophrenia

NCT00295048
View directory record Official record
Conditions
Schizophrenia
Interventions
Computer Assisted Cognitive Remediation (CACR)
Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
3
States / cities
Baltimore, Maryland • Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Oct 21, 2026, 1:41 AM EDT
Completed Not applicable Interventional

Rochester Forensic Assertive Community Treatment Model in Minnesota

NCT07592884
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Criminal Behavior
Interventions
R-FACT intervention, Standard Outpatient Treatment
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 21, 2026, 1:41 AM EDT
Completed Not applicable Interventional

An Exploratory, Double-arm, 8-week Study to Explore the Feasibility and Acceptability of Abbreviated Treatment with CT-156 in People with Schizophrenia.

NCT06486948
View directory record Official record
Conditions
Schizophrenia
Interventions
CT-156
Device
Lead sponsor
Click Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Oct 21, 2026, 1:41 AM EDT
Terminated Phase 4 Interventional

Alcoholism and Schizophrenia: Effects of Clozapine

NCT00169026
View directory record Official record
Conditions
Schizophrenia, Dual Diagnosis, Schizoaffective Disorder, Psychotic Disorder, Substance Abuse, Alcohol Abuse
Interventions
Clozapine versus typical (conventional) and atypical antipsychotic medications
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
19 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Jamaica Plain, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Oct 21, 2026, 1:41 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Placebo-controlled Efficacy Study of IV Ceftriaxone for Refractory Psychosis

NCT00591318
View directory record Official record
Conditions
Psychosis, Schizophrenia, Schizoaffective Disorder
Interventions
ceftriaxone, Normal Saline
Drug
Lead sponsor
Research Foundation for Mental Hygiene, Inc.
Other
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 2, 2022 · Synced Oct 21, 2026, 1:41 AM EDT
Completed Not applicable Interventional Results available

rTMS as a Probe of Episodic Memory Neurocircuitry in Schizophrenia

NCT04182113
View directory record Official record
Conditions
Schizophrenia
Interventions
1 Hz rTMS Stimulation, Sham rTMS Stimulation
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 40 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 28, 2023 · Synced Oct 21, 2026, 1:41 AM EDT
Completed No phase listed Observational

Risk Perception in Drug-Dependent Adults With and Without Schizophrenia

NCT01031563
View directory record Official record
Conditions
Cocaine Dependence, Cannabis Dependence, Schizophrenia
Interventions
Not listed
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 64 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 21, 2026, 1:41 AM EDT
Completed Phase 3 Interventional Results available

A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia

NCT01529515
View directory record Official record
Conditions
Schizophrenia
Interventions
PP3M 175 mg eq., PP3M 263 mg eq., PP3M 350 mg eq., PP3M 525 mg eq., Placebo (20% Intralipid emulsion)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
15
States / cities
Little Rock, Arkansas • San Fran Cisco, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated May 11, 2016 · Synced Oct 21, 2026, 1:41 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Elpipodect (MK-8189) in Participants With an Acute Episode of Schizophrenia (MK-8189-008)

NCT04624243
View directory record Official record
Conditions
Schizophrenia
Interventions
Elpipodect, Risperidone, Placebo to MK-8189, Placebo to risperidone
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
35
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 21, 2026, 1:41 AM EDT
Completed Not applicable Interventional Results available

Contingency Management of Alcohol Abuse in the Severely Mentally ILL

NCT01567943
View directory record Official record
Conditions
Alcohol Abuse, Schizophrenia, Bipolar Disorder, Major Depressive Disorder
Interventions
Contingency Management
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 65 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 21, 2026, 1:41 AM EDT